Biological 'Brake' Discovered: How Fat Molecules Naturally Stop Inflammation

2026-01-21 biotech

London, Wednesday 21 January 2026
UCL researchers have identified a natural mechanism within fat molecules that halts inflammation, successfully reducing pain and harmful immune cells in human trials without compromising the wider immune system.

Unlocking the Body’s Natural Resolution Pathways

In a significant advancement for immunology and the treatment of chronic conditions, researchers at University College London (UCL) have mapped a biological route that actively resolves inflammation in humans [1][2]. Published in Nature Communications on 19 January 2026, the study identifies a mechanism involving fat-derived molecules known as epoxy-oxylipins, which function as an intrinsic ‘off switch’ for the immune response [2][3]. Unlike traditional anti-inflammatory treatments that often suppress the immune system broadly, this discovery suggests a method to support the body’s natural timing—ensuring the immune response remains robust against threats but subsides once the danger has passed [2]. This development holds particular promise for patients suffering from rheumatoid arthritis and cardiovascular disease, offering a potential alternative to long-term reliance on painkillers or steroids [4][5].

The Mechanism: From Fat Molecules to Immune Brakes

The research focuses on the interaction between epoxy-oxylipins and an enzyme called soluble epoxide hydrolase (sEH) [1][6]. Under normal conditions, sEH breaks down epoxy-oxylipins, preventing them from accumulating [6]. However, the UCL team utilised a drug, GSK2256294, to inhibit sEH activity [1]. By blocking this enzyme, the concentration of epoxy-oxylipins increased, effectively engaging the body’s natural braking system for inflammation [3]. Specifically, the study highlighted the role of the epoxy-oxylipin molecule 12,13-EpOME, which was found to shut down p38 MAPK, a critical protein signalling pathway that drives the transformation of immune cells [1][4]. This process prevents the buildup of intermediate monocytes—immune cells associated with chronic inflammation and tissue damage—thereby facilitating a return to homeostasis [6].

Clinical Trial Design and Efficacy

To validate this mechanism in a human setting, the researchers conducted a controlled trial involving healthy volunteers who received injections of UV-killed E. coli bacteria to induce a temporary, localised inflammatory response [1][4]. The participants were divided into two distinct groups totalling 48 volunteers [2][6]. The prophylactic arm received the sEH inhibitor two hours before the induction of inflammation, while the therapeutic arm received the drug four hours after inflammation had started [6]. In both cohorts, the administration of GSK2256294 resulted in a marked reduction in intermediate monocytes in both blood and tissue [1][6]. Furthermore, while external signs such as redness and swelling remained largely unchanged, the participants experienced accelerated pain resolution [4][6]. Dr Olivia Bracken, a lead researcher from the UCL Department of Aging, Rheumatology and Regenerative Medicine, noted that these findings reveal a pathway that limits harmful immune cell expansion without weakening the system excessively [1].

Broader Implications for Autoimmune Treatment

The implications of this study extend beyond the immediate mechanism of action. Professor Derek Gilroy, an author of the study, emphasised that this represents the first time epoxy-oxylipin activity has been mapped in humans during actual inflammation [1]. Given that the drug GSK2256294 has already been deemed safe for human use, the pathway to clinical testing for conditions like rheumatoid arthritis could be expedited [3]. This research arrives amidst a wider focus on early intervention in autoimmune disorders. Concurrently, in January 2026, findings from King’s College London highlighted that the drug abatacept could delay the onset of rheumatoid arthritis by up to four years in high-risk individuals [7]. Together, these developments signal a shift in medical strategy from managing symptoms to precisely modulating the immune timeline [2][7].

Summary

The identification of epoxy-oxylipins as a natural brake on inflammation offers a credible new direction for treating chronic inflammatory diseases [4]. By inhibiting the sEH enzyme, researchers have demonstrated the ability to reduce pain and harmful monocyte levels in humans, potentially paving the way for therapies that restore immune balance rather than suppressing it [3][4]. As clinical trials are anticipated to explore these inhibitors further, the prospect of more effective, targeted pain management options for arthritis and heart disease patients becomes increasingly tangible [1][4].

Sources & Ecosystem Partners

Immunology Therapeutic targets